10x Genomics (NASDAQ:TXG) Releases Earnings Results, Beats Expectations By $0.05 EPS

10x Genomics (NASDAQ:TXG) issued its quarterly earnings results on Thursday. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.05, Zacks reports. The firm had revenue of $149.00 million during the quarter, compared to the consensus estimate of $142.50 million. 10x Genomics had a negative return on equity of 11.71% and a negative net margin of 11.89%.The company’s revenue was down 1.7% on a year-over-year basis. During the same period last year, the company earned ($0.30) earnings per share. 10x Genomics updated its Q4 2025 guidance to EPS.

10x Genomics Price Performance

10x Genomics stock traded up $2.25 during mid-day trading on Friday, reaching $15.25. 7,828,524 shares of the stock traded hands, compared to its average volume of 2,626,219. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $17.25. The business’s 50-day moving average is $12.81 and its 200-day moving average is $11.74. The stock has a market capitalization of $1.90 billion, a PE ratio of -24.60 and a beta of 2.13.

Analysts Set New Price Targets

Several analysts recently commented on TXG shares. Morgan Stanley cut their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 12th. Deutsche Bank Aktiengesellschaft set a $14.00 price target on shares of 10x Genomics and gave the company a “hold” rating in a report on Friday, August 8th. Piper Sandler started coverage on shares of 10x Genomics in a report on Thursday, September 11th. They issued a “neutral” rating and a $15.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on 10x Genomics from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a report on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $14.58.

Insider Buying and Selling at 10x Genomics

In other news, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the transaction, the insider owned 440,888 shares in the company, valued at $6,079,845.52. This trade represents a 1.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Serge Saxonov sold 9,348 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the sale, the chief executive officer owned 945,892 shares of the company’s stock, valued at $13,043,850.68. This trade represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 39,149 shares of company stock worth $539,865 in the last three months. 9.39% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its stake in 10x Genomics by 203.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after purchasing an additional 5,025 shares during the period. Legal & General Group Plc boosted its position in shares of 10x Genomics by 5.7% during the second quarter. Legal & General Group Plc now owns 110,864 shares of the company’s stock worth $1,284,000 after acquiring an additional 5,985 shares during the last quarter. Invesco Ltd. grew its stake in 10x Genomics by 5.4% during the second quarter. Invesco Ltd. now owns 201,739 shares of the company’s stock valued at $2,336,000 after acquiring an additional 10,407 shares in the last quarter. Focus Partners Wealth purchased a new position in 10x Genomics during the first quarter valued at $92,000. Finally, Sei Investments Co. bought a new stake in 10x Genomics in the 2nd quarter valued at $151,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.